has been associated with a poor prognosis for malignant astrocytoma 2, 14, 21 and the reduced expression of p27 in oligodendrocytes has proved to be an independent poor prognostic factor. 3 Kirla, et al., 14 analyzed the expression of p21 and p27 in a high-grade astrocytoma and found that only p27 had an independent prognostic value, although both p27 and p21 were parallel cell cycle regulators.
The main inhibitory action of p27 arises from its binding to the cyclin E/Cdk2 complex and its dephosphorylation of pRB. 6 Throughout the cell cycle p27 mRNA levels remain constant and p27 protein levels are mainly regulated by ubiquitin-mediated proteolysis. This regulation of p27 is linked to the phosphorylation of the protein at Thr187, followed by ubiquitination and proteasome-mediated proteolysis. 23 In addition to its role as a CDKI, p27 acts as a putative tumor suppressor gene: p27-knockout mice have reportedly developed multiorgan hyperplasia and parathyroid tumor, 10 and p27 haplo-insufficient mice have become more sensitive to tumor development induced by radiation or chemical carcinogens. 9 Adenoviral gene transfer of p27 has been shown to induce cell cycle arrest and apoptosis in breast cancer cell lines 7 and we have already demonstrated that the transduction of p27 via an adenoviral vector into human lung cancer vitro tumorigenicity, a soft agar clonogenic assay was performed. Briefly, tumor cells (U373MG and U87MG) were transduced with 20 MOI of ad-p27wt or ad-p27mt and then detached and plated in 0.2% agarose with a 1% agarose underlayer (5 ϫ 10 3 cells/plate). Colonies whose extension was greater than 125 m were counted after 3 weeks by using a calibrated graticule.
Results

Transduction With Ad-p27wt and Ad-p27mt Produced p27 Protein and Induced Dephosphorylation of pRB
A Western blot assay performed to detect p27 among proteins extracted from ad-p27wt-and ad-p27mt-transduced brain tumor cells showed an overexpression of p27 protein. Wild-type p27 and mutant p27 could not be distinguished by using the Western blot assay, but the amount of mutant p27 was significantly higher than that of wild-type p27. Both wild-type and mutant p27 induced pRB dephosphorylation (Fig. 1) .
A More Potent Effect by Ad-p27mt on the Growth Arrest of Human Malignant Gliomas
In the four GBM cell lines, including one primary GBM cell line, ad-p27mt induced a stronger growth suppression than ad-p27wt, which indicates that mutant p27 more potently induces growth arrest in malignant glioma cell lines (Fig. 2) .
Different Patterns of Arrest Induced by Ad-p27wt and Ad-p27mt
Both ad-p27wt and ad-p27mt induced growth arrest in two brain tumor cell lines (U373MG and U87MG) but the patterns of this arrest differed. The Ad-p27wt induced arrest at the G 1 -S transition point, which was manifested by a decrease in the proportion of cells in the S phase and an increase in the proportion of cells in the G 0 -G 1 phase compared with control groups. On the other hand, ad-p27mt induced arrest at the G 2 -M transition point, as shown by a decrease in the proportion of cells in the S phase and an increase in the proportion of cells in the G 2 -M phase ( Fig. 3 and Table 1 ).
More Potent Induction of Apoptosis by Ad-p27mt Than by Ad-p27wt
The Annexin V assay showed that both ad-p27mt and adp27wt induced apoptosis, although their effects were not strong. Nevertheless, ad-p27mt proved to be the more effective inducer of apoptosis. The proportions of apoptotic cells (annexin V-positive and propidium iodide-negative cells) in the U373MG cell line were 2.84% of the nontransduced cells, 4.02% of the ad-lacZ-transduced cells, 8.46% of the ad-p27wt-transduced cells, and 12.9% of the ad-p27mt-transduced cells. In the T98G cell line, cells displaying early apoptosis accounted for 2.96% of the nontransduced cells, 1.84% of the ad-lacZ-transduced cells, 4.86% of the adp27wt-transduced cells, and 8.78% of the ad-p27mt-transduced cells. Although both ad-p27wt and ad-p27mt only induced weak apoptosis, ad-p27mt was the more potent of the two adenoviruses (Fig. 4) .
Stronger Suppression of Tumorigenicity in Malignant Glioma Cell Lines Following Transduction With Ad-p27mt
Transduction with ad-p27wt or ad-p27mt almost completely abolished the clonogenic ability of U373MG cells in soft agar. In U87MG cells, however, ad-p27mt induced a stronger suppression than ad-p27wt, although both ade- noviruses significantly suppressed in vitro tumorigenicity (Fig. 5) .
Discussion
In contrast to other neoplasms, brain tumors occur in a closed space, are relatively small, and have a low metastatic potential. These characteristics make brain tumors an ideal target for direct-acting gene therapy. Nevertheless, current gene therapy trials have thus far failed to show clinically significant responses.
The p27 gene is a member of the multifunctional universal CDKI family and a putative tumor suppressor gene that is rarely mutated in tumors. The reduced expression of p27 in a brain tumor is associated with a poor prognosis, 2, 14, 21 as is the case with other tumors. 22 In colorectal cancer and in non-small cell lung cancer, a reduced level of p27 expression is related to proteasome-mediated proteolysis. 8, 17 In the human glioma cell lines T98G and NAC6, which display contact inhibition within in vitro cultures, the expression of p27 was markedly enhanced; however, no enhancement was found in glioma cell lines without contact inhibition, such as A172 and U251 cells.
11
A high p27 degradation activity was found in highly ma-K. Park, et al. Table 1 ). A cell cycle analysis was performed using flow cytometry 72 hours after transduction with the indicated viruses. To synchronize the cell cycle, the cells were kept in 0.5% FBS containing medium for 24 hours after adenoviral transduction. The numbers of cells are indicated on the y axis and the relative DNA contents in the cells are shown by channels on the x axis. The first peak represents the proportion of cells displaying 2N DNA content (G 0 -G 1 phase) and the second peak represents the proportion of cells showing 4N DNA content (G 2 -M phase). The intervening area signifies the cell fraction measured during the S phase. Typically, G 1 -S arrest exhibited an increase in the cell fraction in the G 0 -G 1 phase and a decrease in this fraction in the S phase, whereas G 2 -M arrest exhibited an increase in the cell fraction in the G 2 -M phase and a decrease in this fraction in the S phase.
FIG. 3. Graphs demonstrating that ad-p27wt induced G 1 -S arrest, whereas ad-p27mt induced G 2 -M arrest in U373MG cells (data for U87MG cells are shown in
lignant gliomas with low-to-absent p27 expression. 20 In the same study the proteasome inhibitor, LLnL, abolished enhanced p27 degradation in a malignant glioma. The overexpression of p27 delivered through adenoviral gene transfer suppressed breast cancer cell growth regardless of the presence of p27 mutation. 7 In a gliosis model, but not in a brain tumor model, p27 overexpression due to delivery of p27 through an adenoviral vector, inhibited astrocyte proliferation and was accompanied by a downregulation of cyclin A. 15 This finding indicates a potential role for p27 in cases of malignant glioma.
In this study, we attempted to develop an ad-p27 gene therapy for malignant glioma and to potentiate its antitumor effect by manipulating the p27 metabolic pathway. As we described, the metabolism of p27 depends on its phosphorylation at Thr187 and subsequent ubiquitination. Graphs showing that ad-p27mt more potently induced apoptosis. In addition to CDKI, an annexin V assay showed that both ad-p27wt and ad-p27mt were effective at inducing apoptosis, which became evident 96 hours after transduction. It is also apparent that ad-p27mt induces apoptosis more potently than ad-p27wt. (Percentage represents the proportion of cells in the early apoptotic portion: that is, while staining positively with annexin V and not for propidium). the stronger antitumor effect of ad-p27mt compared with that of ad-p27wt in a lung-cancer model, despite the fact that both vectors produced distinct antitumor effects. 18, 19 A Western blot assay for p27 showed that the transduction of both adenoviruses induced p27 protein overexpression and pRB dephosphorylation in a GBM cell line. Furthermore, the amount of mutant p27 was significantly higher than that of wild-type p27 protein, indicating that mutant p27 has a long half-life, because the infection doses (MOIs) of both adenoviruses were identical. In addition, in previous work we showed that mutant p27 is more stable than the wild type by using a 35 S-pulse-chase experiment. 18 The p27 protein is a CDKI that affects the cell cycle in multiple steps. Wild-type p27 produced by ad-p27wt induced G 1 -S arrest as expected; however, mutant p27 induced G 2 -M arrest and increased cellular DNA content. In a previous experiment in which we used lung cancer cell lines, both types of p27 were found to induce G 1 -S arrest. 18 We do not have any explanation for this discrepancy; however, it may be related to tissue specificity.
In the present study, the growth assay showed that adp27mt caused more growth suppression than ad-p27wt in all the GBM cell lines that were tested (T98G, U373MG, and U87MG) as well as in a primary GBM cell line, even though both types of vectors effectively blocked cancer cell growth.
A soft agar clonogenic assay also produced the same result, especially in U87MG cells. The clonogenicity of the GBM cell lines was more strongly suppressed by ad-p27mt than by ad-p27wt.
The antitumor effect of ad-p27 was not influenced by the p53 status of the cell line. Both U87MG (wild-type p53) and U373MG (mutant p53) cells were suppressed by p27 gene therapy. More importantly, a primary GBM cell line, established from a specimen obtained at surgery, was also greatly inhibited. This finding strongly indicates the clinical potential of p27 gene therapy in malignant glioma.
In conclusion, this study demonstrates, for the first time, the potential of p27 gene therapy via an adenoviral vector in malignant glioma and a means of enhancing the antitumor effect of p27 by using an adenovirus that expresses a mutant p27 in which the mutation is located at a major metabolic site.
